Growth Metrics

Sarepta Therapeutics (SRPT) Short term Debt: 2011-2025

Historic Short term Debt for Sarepta Therapeutics (SRPT) over the last 7 years, with Sep 2025 value amounting to $36.0 million.

  • Sarepta Therapeutics' Short term Debt fell 60.70% to $36.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $36.0 million, marking a year-over-year decrease of 60.70%. This contributed to the annual value of $105.5 million for FY2023, which is N/A change from last year.
  • Per Sarepta Therapeutics' latest filing, its Short term Debt stood at $36.0 million for Q3 2025, which was down 60.70% from $91.6 million recorded in Q3 2024.
  • Over the past 5 years, Sarepta Therapeutics' Short term Debt peaked at $105.6 million during Q1 2024, and registered a low of $36.0 million during Q3 2025.
  • Its 3-year average for Short term Debt is $86.0 million, with a median of $91.6 million in 2024.
  • Data for Sarepta Therapeutics' Short term Debt shows a maximum YoY crashed of 60.70% (in 2025) over the last 5 years.
  • Quarterly analysis of 3 years shows Sarepta Therapeutics' Short term Debt stood at $105.5 million in 2023, then reached $91.6 million in 2024, then plummeted by 60.70% to $36.0 million in 2025.
  • Its Short term Debt was $36.0 million in Q3 2025, compared to $91.6 million in Q3 2024 and $91.5 million in Q2 2024.